Infliximab, azathioprine, or combination therapy for Crohn's disease.
By J. Colombel, W. Sandborn, W. Reinisch, G. Mantzaris, A. Kornbluth, D. Rachmilewitz, S. Lichtiger, G. D'Haens, R. Diamond, D. Broussard and 3 more. New England Journal of Medicine, 2010
2,986 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/e1dd7e1427a02136dda28467895a8ede6c26e334
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Immunology
In Rheumatology
Citations in the corpus
- Guidelines for the management of inflammatory bowel disease in adults (2011, result): “It is unclear as to whether patients should be treated with solely anti-TNF monotherapy or with concomitant immunosuppression. The balance of argument pivots on the need to optimise anti-TNF therapy and the increased risk of complications associated with the latter. The recent SONIC study evaluated ”
- Mucosal healing in inflammatory bowel diseases: a systematic review (2012, background): “MUCOSAL HEALING IN CROHN’S DISEASE Almost all studies in Crohn’s disease use the CDAI as the primary endpoint, although many assess mucosal healing as a secondary endpoint.(96) The notable exception is the EXTEND study of 135 patients with Crohn’s disease,(101) which used complete mucosal healing (a”